Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging

Antoine D’Hollander,1–3 Evelien Mathieu,1,4 Hilde Jans,1 Greetje Vande Velde,2,3 Tim Stakenborg,1 Pol Van Dorpe,1,4 Uwe Himmelreich,2,3 Liesbet Lagae1,4 1Department of Life Science Technology, Imec, 2Department of Imaging and Pathology, Faculty of Medicine, Biomedical MRI Unit,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	D’Hollander A, Mathieu E, Jans H, Vande Velde G, Stakenborg T, Van Dorpe P, Himmelreich U, Lagae L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	SERS - Gold Nanostars - Cancer Imaging Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4bb786e4d813423d9c2bcb7e7f32daeb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4bb786e4d813423d9c2bcb7e7f32daeb
record_format	dspace
spelling	oai:doaj.org-article:4bb786e4d813423d9c2bcb7e7f32daeb2021-12-02T03:54:13ZDevelopment of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging1178-2013https://doaj.org/article/4bb786e4d813423d9c2bcb7e7f32daeb2016-08-01T00:00:00Zhttps://www.dovepress.com/development-of-nanostars-as-a-biocompatible-tumor-contrast-agent-towar-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Antoine D’Hollander,1–3 Evelien Mathieu,1,4 Hilde Jans,1 Greetje Vande Velde,2,3 Tim Stakenborg,1 Pol Van Dorpe,1,4 Uwe Himmelreich,2,3 Liesbet Lagae1,4 1Department of Life Science Technology, Imec, 2Department of Imaging and Pathology, Faculty of Medicine, Biomedical MRI Unit, 3Faculty of Medicine, Molecular Small Animal Imaging Center (MoSAIC), 4Department of Physics, Faculty of Sciences, Laboratory of Solid State Physics and Magnetism, KU Leuven, Leuven, Belgium Abstract: The need for sensitive imaging techniques to detect tumor cells is an important issue in cancer diagnosis and therapy. Surface-enhanced Raman scattering (SERS), realized by chemisorption of compounds suitable for Raman spectroscopy onto gold nanoparticles, is a new method for detecting a tumor. As a proof of concept, we studied the use of biocompatible gold nanostars as sensitive SERS contrast agents targeting an ovarian cancer cell line (SKOV3). Due to a high intracellular uptake of gold nanostars after 6 hours of exposure, they could be detected and located with SERS. Using these nanostars for passive targeting after systemic injection in a xenograft mouse model, a detectable signal was measured in the tumor and liver in vivo. These signals were confirmed by ex vivo SERS measurements and darkfield microscopy. In this study, we established SERS nanostars as a highly sensitive contrast agent for tumor detection, which opens the potential for their use as a theranostic agent against cancer. Keywords: SERS, gold nanostars, cancer imaging, Raman activeD’Hollander AMathieu EJans HVande Velde GStakenborg TVan Dorpe PHimmelreich ULagae LDove Medical PressarticleSERS - Gold Nanostars - Cancer ImagingMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 3703-3714 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	SERS - Gold Nanostars - Cancer Imaging Medicine (General) R5-920
spellingShingle	SERS - Gold Nanostars - Cancer Imaging Medicine (General) R5-920 D’Hollander A Mathieu E Jans H Vande Velde G Stakenborg T Van Dorpe P Himmelreich U Lagae L Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
description	Antoine D’Hollander,1–3 Evelien Mathieu,1,4 Hilde Jans,1 Greetje Vande Velde,2,3 Tim Stakenborg,1 Pol Van Dorpe,1,4 Uwe Himmelreich,2,3 Liesbet Lagae1,4 1Department of Life Science Technology, Imec, 2Department of Imaging and Pathology, Faculty of Medicine, Biomedical MRI Unit, 3Faculty of Medicine, Molecular Small Animal Imaging Center (MoSAIC), 4Department of Physics, Faculty of Sciences, Laboratory of Solid State Physics and Magnetism, KU Leuven, Leuven, Belgium Abstract: The need for sensitive imaging techniques to detect tumor cells is an important issue in cancer diagnosis and therapy. Surface-enhanced Raman scattering (SERS), realized by chemisorption of compounds suitable for Raman spectroscopy onto gold nanoparticles, is a new method for detecting a tumor. As a proof of concept, we studied the use of biocompatible gold nanostars as sensitive SERS contrast agents targeting an ovarian cancer cell line (SKOV3). Due to a high intracellular uptake of gold nanostars after 6 hours of exposure, they could be detected and located with SERS. Using these nanostars for passive targeting after systemic injection in a xenograft mouse model, a detectable signal was measured in the tumor and liver in vivo. These signals were confirmed by ex vivo SERS measurements and darkfield microscopy. In this study, we established SERS nanostars as a highly sensitive contrast agent for tumor detection, which opens the potential for their use as a theranostic agent against cancer. Keywords: SERS, gold nanostars, cancer imaging, Raman active
format	article
author	D’Hollander A Mathieu E Jans H Vande Velde G Stakenborg T Van Dorpe P Himmelreich U Lagae L
author_facet	D’Hollander A Mathieu E Jans H Vande Velde G Stakenborg T Van Dorpe P Himmelreich U Lagae L
author_sort	D’Hollander A
title	Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
title_short	Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
title_full	Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
title_fullStr	Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
title_full_unstemmed	Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging
title_sort	development of nanostars as a biocompatible tumor contrast agent: toward in vivo sers imaging
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/4bb786e4d813423d9c2bcb7e7f32daeb
work_keys_str_mv	AT dhollandera developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT mathieue developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT jansh developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT vandeveldeg developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT stakenborgt developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT vandorpep developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT himmelreichu developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging AT lagael developmentofnanostarsasabiocompatibletumorcontrastagenttowardinvivosersimaging
_version_	1718401546311434240

Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging

Ejemplares similares